财报对对碰丨风口上的重组胶原蛋白生意:锦波生物毛利率连涨4年,巨子生物连年下滑

中新经纬
25 Apr

中新经纬4月25日电 (林琬斯)重组胶原蛋白生意正成新风口。近日,分别被称为港股与北交所“重组胶原蛋白第一股”的巨子生物、锦波生物相继交出2024年度成绩单:锦波生物净利翻倍,巨子生物的经调整净利是前者归母净利润的将近3倍。不过,细看两家企业的毛利率能发现,锦波生物毛利率连涨4年,巨子生物连年下滑,这是为什么?巨子生物可复美贡献超八成营收2024年年报显示,巨子生物当年实现营业收入55.39亿元,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10